Under the agreement, Forge, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), will provide adeno-associated viral (AAV) vector process and analytical development, scale-up engineering, and good manufacturing practice (GMP) manufacturing services for GentiBio's therapeutic candidates based on the company's engineered T regulatory cells (Tregs).
GentiBio's autologous and allogeneic EngTregs platform restores immune tolerance to overcome major limitations in existing Tregs therapeutics.
GentiBio's process development will utilize Forge's Blaze Vector production platform as well as HEK 293 suspension ignition cells. All development and GMP activities will take place at Forge's 175,000-sq-ft facility in Columbus, OH.
Financial details of the partnership were not disclosed.
Copyright © 2021 scienceboard.net
Read Again https://www.scienceboard.net/index.aspx?sec=log&itemID=2999
Bagikan Berita Ini
Related Posts :
Kanawha Manufacturing Company property to be redeveloped - WCHS- Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site - Yahoo Finance
- Swiss manufacturing giant announces $184M factory in Augusta - The Atlanta Journal Constitution
- Union, Case reach contract agreement, averting strike at Fargo manufacturing plant - KFGO
- Gov. Kemp announces hundreds of e-mobility manufacturing jobs coming to east central Georgia - WSB Atlanta
0 Response to "Forge Biologics to develop, manufacture GentiBio therapies - The Science Board"
Post a Comment